Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
The old herbal drug aristolochic acid (AA), derived from Aristolochia spp., has been associated with the development of a novel nephropathy, designated aristolochic acid nephropathy (AAN), and urothelial cancer in AAN patients. There is clear evidence that the major components of the plant extract AA, aristolochic acid I (AAI) and aristolochic acid II (AAII), both nitrophenanthrene carboxylic acids, are genotoxic mutagens forming DNA adducts after metabolic activation through simple reduction of the nitro group. Several mammalian enzymes have been shown to be capable of activating both AAI and AAII in vitro and in cells. The activating metabolism has been elucidated and is consistent with the formation of a cyclic nitrenium ion with delocalized charge leading to the preferential formation of purine adducts bound to the exocyclic amino groups of deoxyadenosine and deoxyguanosine. The predominant DNA adduct in vivo, 7-(deoxyadenosin-N(6)-yl)aristolactam I (dA-AAI), which is the most persistent of the adducts in target tissue, is a mutagenic lesion leading to AT-->TA transversions in vitro. This transversion mutation is found at high frequency in codon 61 of the H-ras oncogene in tumours of rodents induced by AAI, suggesting that dA-AAI might be the critical lesion in the carcinogenic process in rodents. DNA-binding studies confirmed that both AAs bind to the adenines of codon 61 in the H-ras mouse gene and preferentially to purines in the human p53 gene. In contrast, the molecular mechanism of renal interstitial fibrosis in humans after chronic administration of AA remains to be explored. However, preliminary findings suggest that DNA damage by AA is not only responsible for the tumour development but also for the destructive fibrotic process in the kidney. It is concluded that there is significant evidence that AA is a powerful nephrotoxic and carcinogenic substance with an extremely short latency period, not only in animals but also in humans. In particular, the highly similar metabolic pathway of activation and resultant DNA adducts of AA allows the extrapolation of carcinogenesis data from laboratory animals to the human situation. Therefore, all products containing botanicals known to or suspected of containing AA should be banned from the market world wide.
Arlt
Volker M
VM
Section of Molecular Carcinogenesis, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK. v.arlt@icr.ac.uk
Stiborova
Marie
M
Schmeiser
Heinz H
HH
D000818:Animals; D034341:Aristolochic Acids / Q000009:adverse effects* / Q000378:metabolism / Q000633:toxicity; D001449:Balkan Nephropathy / Q000139:chemically induced; D002273:Carcinogens / Q000633:toxicity; D018736:DNA Adducts; D004365:Drugs, Chinese Herbal / Q000009:adverse effects; D029001:Herbal Medicine; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D009153:Mutagens / Q000633:toxicity; D009369:Neoplasms / Q000139:chemically induced*; D009395:Nephritis, Interstitial / Q000139:chemically induced*; D009793:Ochratoxins / Q000009:adverse effects; D012377:Rodentia
D034341:Aristolochic Acids; D002273:Carcinogens; D018736:DNA Adducts; D004365:Drugs, Chinese Herbal; D009153:Mutagens; D009793:Ochratoxins; C025589:ochratoxin A; C000228:aristolochic acid I